A Phase 4 interventional study of Conventional low protein diet and Very low protein diet supplemented with Ketosteril in Chronic Kidney Disease, sponsored by Anemia Working Group Romania. Completed at 1 site in Romania. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-12-22.
Sponsored by Anemia Working Group Romania · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Renal Insufficiency, Chronic with a site in Romania — 8 open to participants now, 11 under way, 7 of them phase 3. Renal Insufficiency, Chronic · Romania.
Among the 65 studies in Renal Insufficiency, Chronic with a site in Romania, this one is the 35th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2008, is one of 4 in phase 4, and was the 29th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →8 of the 65 studies in Renal Insufficiency, Chronic with a site in Romania are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Romania, United States, Argentina and 24 more countries
Ages 18–99
AstraZeneca · Sites in Romania, United States, Argentina and 34 more countries
Ages 18+
Stefan Lujinschi · Sites in Romania
Ages 18+
Eli Lilly and Company · Sites in Romania, Argentina, Australia and 35 more countries
Ages 50+
AstraZeneca · Sites in Romania, United States, Argentina and 39 more countries
Ages 18+
A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 40 · Phase 4 4
First in 2004; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 250 is above the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 455 across the 56 interventional studies, 200 across the 9 observational. Of the 50 that completed or were terminated, 34 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 65 have an industry lead sponsor. The 10 most frequent:
Anemia Working Group Romania is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Anemia Working Group Romania has 4 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
3 of the studies in Renal Insufficiency, Chronic with a site in Romania that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
| NCT07237451Grigore T. Popa University of Medicine and PharmacyCardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients | 2027-03-01 |
| NCT07697469Grigore T. Popa University of Medicine and PharmacyAtrial Cardiomyopathy in Patients With Cardiovascular-Kidney-Metabolic Syndrome: Non-invasive Characterization | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies in Renal Insufficiency, Chronic with a site in Romania, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective single center randomized controlled trial with a total duration of 18 months aiming to evaluate the effectiveness and the safety of a very low protein diet supplemented with ketoanalogues of essential aminoacids in reducing the progression of chronic kidney disease (CKD) in patients with advanced CKD.
All eligible patients who will give informed consent will be screened. Those meeting the selection criteria will be enrolled and will enter a 3-month run-in phase during which a conventional LPD will be prescribed in all patients.
At the end of this phase, the subjects still fulfilling all the selection criteria will be randomized in a 1:1 ratio to receive the KD or to continue the conventional LPD for a total duration of 15 months.
Nineteen blood and urine samplings are scheduled for each patient, to be drawn monthly. The laboratory reports include the nitrogen compounds, calcium-phosphorus metabolism parameters, acid-base balance, biochemical nutritional markers, serum C-reactive protein, hemoglobin, blood cell count, and biochemical safety parameters (sodium, potassium, liver enzymes, and bilirubin).
The anthropometric measurements and subjective global assessment will be evaluated at enrolment, at randomization, and every 3 months thereafter.
The compliance with the prescribed diet (protein and energy intake) will be assessed monthly during the run-in phase, weekly for the first month after randomization, every 4 weeks during the next 6 months, and every 3 months thereafter.
The blood pressure levels, drugs required for the therapy of hypertension, acidosis and mineral metabolism disorders, and occurrence of adverse events will be recorded monthly.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients in the intervention arm (KD group) will receive a vegetarian very low protein diet (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day.
Dietary Supplement: Very low protein diet supplemented with Ketosteril
The patients in the control arm (LPD group) will continue their conventional low protein diet, with 0.6 g/kg per day (including high biological value proteins). The total recommended energy intake is of 30 kcal/kg of ideal dry body weight per day in both arms.
Behavioral: Conventional low protein diet
Also known as: LPD, Hypoproteic diet
Also known as: SVLPD, Keto-diet
Primary composite endpoint
Need for renal replacement therapy or an at least 50% reduction in the estimated glomerular filtration rate compared to randomization
Time frame: 15 months after randomization
Secondary efficacy parameter
The rate of decline in the estimated Glomerular Filtration Rate
Time frame: months 3-15 after randomization
Secondary outcome measure - nitrogen balance
variations in serum urea
Time frame: 15 months after randomization
Secondary efficacy parameter - mineral metabolism
variations in total serum calcium
Time frame: 15 weeks after randomization
Secondary efficacy parameter
variations in serum phosphate level
Time frame: 15 weeks after randomization
Secondary efficacy parameter
variations in serum bicarbonate
Time frame: 15 weeks after randomization
Secondary safety parameter
Subjective Global Assessment of the nutritional status
Time frame: 18 weeks after enrolment
Secondary safety parameter
Body Mass Index
Time frame: 18 weeks after enrolment
Secondary outcome measure - Nutritional status
Tricipital skinfold
Time frame: 18 weeks after enrolment
Secondary safety parameter - anthropometric measures
Mid-arm muscular circumference
Time frame: 18 weeks after enrolment
Nutritional status - biochemical markers
serum albumin
Time frame: 18 weeks after enrolment
Inflammation
serum level of C reactive protein
Time frame: 18 weeks after enrolment
Nutritional status - biochemical marker
Serum total cholesterol
Time frame: 18 weeks after enrolment
Secondary safety parameter
Serum potassium level
Time frame: 18 weeks after enrolment
Secondary safety parameter
liver enzymes: Aspartate Aminotransferase, Alanine Transaminase
Time frame: 18 weeks after enrolment
Safety parameter - adverse events
Occurrence of any adverse event
Time frame: 18 weeks after enrolment
Secondary safety parameter - withdrawals
number of withdrawals
Time frame: 18 weeks after enrolment
Compliance - protein intake
urinary urea nitrogen excretion to calculate the protein intake
Time frame: 18 months after enrolment
Compliance - energy intake
3-day food diary to calculate the daily energy intake
Time frame: 18 weeks after enrolment
The record gives a start of Mar 2008, a primary completion of Jun 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Anemia Working Group Romania